title: [Glaucoma as primary optic neuropathy].
abstract: The appearance of the new concept of glaucomatous optic neuropathy directed to idea that high intraocular pressure and vascular insufficiency in the optic nerve head are only risk factors in the appearance of glaucoma. Glaucomatous optic neuropathy is the consequence of progressive loss of the retinal ganglion cells whose axons comprise the optic nerve. A great number of neurotrophic agents are under investigation with the view of preventing the dead of retinal ganglion cells. Induction of cell rescue mechanisms may be an alternate and efficient strategy for neuroprotection. The paper presents both actual data about the pathophysiological mechanisms of glaucoma (neurotrophin deprivation, excitotoxicity caused by glutamate, "ischemic cascade", apoptosis of retinal ganglion cells) and neuroprotective and neuroregenerative therapy and antiapoptotic agents.
authors.affiliation: Clinica de Oftalmologie, Spitalul Clinic de Urgeţă Militar Central, Bucureşti.
authors.forename: A
authors.initials: A
authors.lastname: Nicolae
authors.forename: C
authors.initials: C
authors.lastname: Stefan
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D003000:Clonidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009901:Optic Nerve Diseases / Q000188:drug therapy* / Q000503:physiopathology; D018341:Receptors, Adrenergic, alpha-2 / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D018341:Receptors, Adrenergic, alpha-2; C016986:apraclonidine; D003000:Clonidine; D004837:Epinephrine